Boston Scientific (BSX) Liabilities and Shareholders Equity (2016 - 2025)
Boston Scientific (BSX) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $43.7 billion as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 10.86% to $43.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168.1 billion through Dec 2025, up 11.13% year-over-year, with the annual reading at $43.7 billion for FY2025, 10.86% up from the prior year.
- Liabilities and Shareholders Equity hit $43.7 billion in Q4 2025 for Boston Scientific, up from $42.7 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $43.7 billion in Q4 2025 to a low of $30.9 billion in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $35.5 billion across 5 years, with a median of $33.8 billion in 2023.
- Biggest five-year swings in Liabilities and Shareholders Equity: grew 0.22% in 2022 and later rose 12.16% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $32.2 billion in 2021, then increased by 0.74% to $32.5 billion in 2022, then increased by 8.21% to $35.1 billion in 2023, then increased by 12.12% to $39.4 billion in 2024, then increased by 10.86% to $43.7 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for BSX at $43.7 billion in Q4 2025, $42.7 billion in Q3 2025, and $41.6 billion in Q2 2025.